Naringenin inhibits thoracic aortic aneurysm formation in mice with Marfan syndrome

  • Zhi-qing LI ,
  • Bing YU ,
  • Ze-yu CAI ,
  • Ying-bao WANG ,
  • Xu ZHANG ,
  • Biao ZHOU ,
  • Xiao-hong FANG ,
  • Fang YU ,
  • Yi FU ,
  • Jin-peng SUN ,
  • Wei LI ,
  • Wei KONG
Expand
  • 1. Department of Physiology and Pathophysiology, Peking University School of Basic Medical Sciences, Beijing 100191, China
    2. Department of General Surgery, China-Japan Friendship Hospital, Beijing 100029, China
    3. Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
    4. Department of Vascular Surgery, Peking University People's Hospital, Beijing 100044, China

Received date: 2022-06-03

  Online published: 2022-10-14

Supported by

the National Natural Science Foundation of China(81730010);the National Natural Science Foundation of China(82100480);the National Natural Science Foundation of China(31930056);the National Natural Science Foundation of China(81921001);China Postdoctoral Science Foundation(2020M680257)

Abstract

Objective: To identify whether naringenin plays a protective role during thoracic aneurysm formation in Marfan syndrome. Methods: To validate the effect of naringenin, Fbn1C1039G/+ mice, the mouse model of Marfan syndrome, were fed with naringenin, and the disease progress was evaluated. The molecular mechanism of naringenin was further investigated via in vitro studies, such as bioluminescence resonance energy transfer (BRET), atomic force microscope and radioligand receptor binding assay. Results: Six-week-old Fbn1C1039G/+ mice were fed with naringenin for 20 weeks. Compared with the control group, naringenin significantly suppressed the aortic expansion [Fbn1C1039G/+ vs. Fbn1C1039G/++naringenin: (2.49±0.47) mm, n=18 vs. (1.87±0.19) mm, n=22, P < 0.05], the degradation of elastin, and the expression and activity of matrix metalloproteinase 2 (MMP2) and MMP9 in the ascending aorta of Fbn1C1039G/+ mice. Besides, treatment with naringenin for 6 weeks also attenuated the disease progress among the 20-week-old Fbn1C1039G/+ mice with established thoracic aortic aneurysms [Fbn1C1039G/+ vs. Fbn1C1039G/++naringenin: (2.24±0.23) mm, n=8 vs. (1.90±0.17) mm, n=8, P < 0.05]. To understand the underlying molecular mechanisms, we examined the effects of naringenin on angiotensin Ⅱ type 1 receptor (AT1) signaling and transforming growth factor-β (TGF-β) signaling respectively, which were the dominant signaling pathways contributing to aortopathy in Marfan syndrome as previously reported. The results showed that naringenin decreased angiotensin Ⅱ (Ang Ⅱ)-induced phosphorylation of protein kinase C (PKC) and extracellular regulating kinase 1/2 (ERK1/2) in HEK293A cell overexpressing AT1 receptor. Moreover, naringenin inhibited Ang Ⅱ-induced calcium mobilization and uclear factor of activated T-cells (NFAT) signaling. The internalization of AT1 receptor and its binding to β-arrestin-2 with Ang Ⅱ induction were also suppressed by naringenin. As evidenced by atomic force microscope and radioligand receptor binding assay, naringenin inhibited Ang Ⅱ binding to AT1 receptor. In terms of TGF-β signaling, we found that feeding the mice with naringenin decreased the phosphorylation of Smad2 and ERK1/2 as well as the expression of TGF-β downstream genes. Besides, the serum level of TGF-β was also decreased by naringenin in the Fbn1C1039G/+ mice. Furthermore, we detected the effect of naringenin on platelet, a rich source of TGF-β, both in vivo and in vitro. And we found that naringenin markedly decreased the TGF-β level by inhibiting the activation of platelet. Conclusion: Our study showed that naringenin has a protective effect on thoracic aortic aneurysm formation in Marfan syndrome by suppressing both AT1 and TGF-β signaling.

Cite this article

Zhi-qing LI , Bing YU , Ze-yu CAI , Ying-bao WANG , Xu ZHANG , Biao ZHOU , Xiao-hong FANG , Fang YU , Yi FU , Jin-peng SUN , Wei LI , Wei KONG . Naringenin inhibits thoracic aortic aneurysm formation in mice with Marfan syndrome[J]. Journal of Peking University(Health Sciences), 2022 , 54(5) : 896 -906 . DOI: 10.19723/j.issn.1671-167X.2022.05.017

References

1 Milewicz DM , Braverman AC , De Backer J , et al. Marfan syndrome[J]. Nat Rev Dis Primers, 2021, 7 (1): 64.
2 Holm TM , Habashi JP , Doyle JJ , et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice[J]. Science, 2011, 332 (6027): 358- 361.
3 Habashi JP , Judge DP , Holm TM , et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome[J]. Science, 2006, 312 (5770): 117- 121.
4 Cook JR , Clayton NP , Carta L , et al. Dimorphic effects of transforming growth factor-beta signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome[J]. Arterioscler Thromb Vasc Biol, 2015, 35 (4): 911- 917.
5 Jia Y , Zhang L , Liu Z , et al. Targeting macrophage TFEB-14-3-3 epsilon Interface by naringenin inhibits abdominal aortic aneurysm[J]. Cell Discov, 2022, 8 (1): 21.
6 Rodríguez-Vita J , Sánchez-López E , Esteban V , et al. Angiotensin Ⅱ activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism[J]. Circulation, 2005, 111 (19): 2509- 2517.
7 Touat Z , Lepage L , Ollivier V , et al. Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm[J]. Arterioscler Thromb Vasc Biol, 2008, 28 (5): 940- 946.
8 Metelli A , Salem M , Wallace CH , et al. Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer[J]. J Hematol Oncol, 2018, 11 (1): 24.
9 Fusi F , Trezza A , Tramaglino M , et al. The beneficial health effects of flavonoids on the cardiovascular system: Focus on K(+) channels[J]. Pharmacol Res, 2020, 152, 104625.
10 Burke AC , Sutherland BG , Telford DE , et al. Naringenin enhances the regression of atherosclerosis induced by a chow diet in Ldlr (-/-) mice[J]. Atherosclerosis, 2019, 286, 60- 70.
11 Wisler JW , Harris EM , Raisch M , et al. The role of beta-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome[J]. Am J Physiol Heart Circ Physiol, 2015, 309 (9): H1516- 1527.
12 Teixido-Tura G , Forteza A , Rodríguez-Palomares J , et al. Losartan versus atenolol for prevention of aortic dilation in patients with marfan syndrome[J]. J Am Coll Cardiol, 2018, 72 (14): 1613- 1618.
13 van Andel MM , Indrakusuma R , Jalalzadeh H , et al. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial[J]. Eur Heart J, 2020, 41 (43): 4181- 4187.
14 Rifkin DB , Rifkin WJ , Zilberberg L . LTBPs in biology and medicine: LTBP diseases[J]. Matrix Biol, 2018, 71/72, 90- 99.
15 Li W , Li Q , Jiao Y , et al. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis[J]. J Clin Invest, 2014, 124 (2): 755- 767.
16 Wei H , Hu JH , Angelov SN , et al. Aortopathy in a mouse model of marfan syndrome is not mediated by altered transforming growth factor beta signaling[J]. J Am Heart Assoc, 2017, 6 (1): e004968.
17 Hernandez-Aquino E , Zarco N , Casas-Grajales S , et al. Naringenin prevents experimental liver fibrosis by blocking TGFbeta-Smad3 and JNK-Smad3 pathways[J]. World J Gastroenterol, 2017, 23 (24): 4354- 4368.
18 Lim W , Song G . Naringenin-induced migration of embrynoic trophectoderm cells is mediated via PI3K/AKT and ERK1/2 MAPK signaling cascades[J]. Mol Cell Endocrinol, 2016, 428, 28- 37.
19 Yang Y , Xu Y , Xia T , et al. A single-molecule study of the inhibition effect of Naringenin on transforming growth factor-beta ligand-receptor binding[J]. Chem Commun (Camb), 2011, 47 (19): 5440- 5442.
20 Lopez JJ , El Haouari M , Jardin I , et al. Flavonoids and platelet-derived thrombotic disorders[J]. Curr Med Chem, 2019, 26 (39): 7035- 7047.
Outlines

/